Ohio born & raised, now loving Dallas! Medical Device Space for 25 years. Love of Family, Friends, Work, Soccer, Cycling, Running, and enjoying the Outdoors!
Interview with Elon Musk from 2012: " My proceeds from PayPal after tax were about $180M, $100M of that went into SpaceX, $70M into Tesla, and $10M into SolarCity and I literally had to borrow money for rent."
Pac-12 bound Cal Poly released its 2026 schedule Thursday!
5⃣games vs. 2025 NCAA Tournament qualifiers
6⃣Pac-12 matchups
🔟Home matchups at Mustang Memorial Field
#RideHigh
📰https://t.co/GwJut4cV9m
Peer-reviewed research published in the European Heart Journal demonstrates that EchoGo® Amyloidosis outperforms traditional clinical scores, including TCAS and IWT, while maintaining consistent performance across amyloidosis subgroups.
With strong diagnostic performance (85% sensitivity, 93% specificity) and low risk of bias, EchoGo® Amyloidosis supports early clinical consideration to help address persistent diagnostic delays.
🔗https://t.co/bs8ArSAlHW
#ATTRCM #CardiacAmyloidosis #CardiacSonography #HealthcareAI
Earlier identification is associated with reduced mortality and fewer heart failure hospitalizations, highlighting the importance of timely detection. EchoGo® Amyloidosis supports identification from routine echocardiography, helping clinicians detect signs of disease before symptoms are overlooked or dismissed.
Learn more at https://t.co/ULqbxZ4qIb
Spencer-Bonilla G et al., JAMA Cardiol. 2026.
Physician perspectives continue to shape the conversation around AI in cardiology. The Verse highlights clinician voices, real-world implementation stories, and conversations around the role EchoGo® can play in supporting the detection of complex diseases like HFpEF and Cardiac Amyloidosis.
Learn more at https://t.co/mEzZPoGp3y
#Echocardiography #Cardiology #AIinHealthcare #HFpEF #CardiacAmyloidosis
🔍Curious how EchoGo® can fit into your echocardiography workflow?
The Verse highlights how EchoGo® is being implemented in practice—showcasing operational utility, clinical credibility, and real-world impact. From expert perspectives to real-world implementation stories, explore how Ultromics' AI is being applied to routine echocardiography. Visit https://t.co/eksSlbfjHu to learn more!
#Echocardiography #Cardiology #AIinHealthcare #HFpEF #ATTRCM
Members of our team will be on site in California for Innovation in Cardiovascular Care: Digital Intelligence & Therapeutic Breakthroughs. We look forward to connecting with attendees and sharing how Ultromics’ clinically validated AI supports detection of HFpEF and Cardiac Amyloidosis.
#DigitalHealth #AIinHealthcare #HFpEF #ATTRCM #Echocardiology
HFpEF doesn’t always present the same way, especially in women. Variability in presentation and symptom overlap can make identification more challenging. Dr. @carinehamo shares key insights in the clip here: https://t.co/F2zK1GvIrv
#HFpEF#HeartFailure#Echocardiography #WomensHealth #AIinHealthcare
From a single apical four-chamber (A4C) view to AI-driven insights.
Ultromics’ EchoGo® platform analyzes a routine A4C clip to support detection of HFpEF and Cardiac Amyloidosis—integrating seamlessly into existing echocardiography workflows. EchoGo® returns results in under 20 minutes to augment clinical decision-making and help guide patients along the appropriate care pathway. Want to learn more? Schedule a demo using the link below.
🔗 https://t.co/G5nw4ai660
#AiInsights #ClinicalInnovation #HFpEF #ATTRCM
In our Febrary webinar, we explored gender disparities in heart failure and the role AI may play in reducing bias and supporting early detection. Moderator and speaker Dr. Sangita Sudharshan opened the discussion by sharing key insights on heart failure and its impact on women. Hear more in the clip below.
🎥 https://t.co/eusbdg4v0q
#ClinicalInnovation #HFpEF #HeartFailure #AiInsights
Hear our latest research tomorrow at #ACC26 as Ultromics’ Jodie Koep, Phd, presents: AI Prediction of ATTR Cardiac Amyloidosis Using Echocardiograms—Clinical Utility in the Case of Equivocal Diagnostic Testing
📢 Jodie Koep, MD
🗓️ Monday, March 30 | ⏰ 11:00 AM – 12:00 PM
📍 Hall E, Session 1564
We look forward to sharing how AI is being applied within echocardiography to support detection of cardiac amyloidosis in challenging diagnostic cases.
#ClinicalInnovation #ATTRCM #CardiacAmyloidosis
Attending #ACC26? Stop by booth 547 to connect with our team and learn how Ultromics’ clinically validated AI analyzes routine echocardiograms to support early detection of complex cardiac diseases, including HFpEF and Cardiac Amyloidosis.
#ClinicalInnovation#HFpEF#ATTRCM #AIinHealthcare
💡 #ACC26: @pattypellikka on the use of AI to support detection of Cardiac Amyloidosis. ATTR-CM remains underrecognized with high morbidity and mortality—highlighting the importance of identifying patients earlier.
Stop by booth 547 to hear more about how EchoGo® Heart Failure and EchoGo® Amyloidosis are being implemented to support early detection.
#ClinicalInnovation #ATTRCM #AmyloidAwareness #AIinHealthcare
We’re proud to share that Ultromics' own Jodie Koep, PHD, will be presenting new research at #ACC26.
AI Prediction of ATTR Cardiac Amyloidosis Using Echocardiograms: Clinical Utility in the Case of Equivocal Diagnostic Testing
🗓️ Monday March 30, from 11am-12pm
📍 Hall E, Session 1564
#CardiacAmyloidosis #ATTRCM #AmyloidosisAwarenessMonth #AmyloidosisAwareness #Echocardiography #ClinicalInnovation #AIinCardiology